Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective single-arm study of telpefilgrastim injection in recurrent implantation failure
ChiCTR2400094723Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Zhengzhou University
- Start
- Dec 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telpefilgrastim in Recurrent Implantation Failure (RIF), sponsored by The Second Affiliated Hospital of Zhengzhou University. Primary endpoints: Safety and tolerability, Pharmacokinetic parameters of telpefilgrastim and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
telpefilgrastim
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on ChiCTR2400094723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094723.